Negative IQWiG view on AstraZeneca's combo diabetes drug Xigduo

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) said it has found no added benefit for Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Xigduo (dapagliflozin and metformin fixed dose combination) for diabetes over the appropriate comparator therapy.

The combination drug was approved by the European Commission earlier this year (The Pharma Letter January 22). However, no added benefit can be derived from the dossier, said the IQWiG, because the drug manufacturer did not present any suitable data for any of the possible therapeutic indications.

Monotherapy or combination therapy possible